CAR-T immune therapies could be effective against solid tumors if the right targets are identified, a new study led by University of Illinois Urbana-Champaign researchers suggests.
Verge Genomics teams up with AstraZeneca in drug discovery deal
Verge Genomics has secured its largest deal yet, linking up with AstraZeneca’s rare disease division Alexion in a deal worth up to $882 million. The
September 9, 2023